A Phase III Study of Thoracic Radiation With or Without Concurrent Cisplatin Chemotherapy in Locoregional Unresectable Non-Small Cell Carcinoma of the Lung
A Multi-Centered Phase I/II Study of Cetuximab in Combination with Paclitaxel and Carboplatin in Untreated Patients with Stage IV Non-Small Cell Lung Cancer
A Phase III Study of Pemetrexed vs Docetaxel in Patients with Recurrent Non-Small Cell Lung Cancer (NSCLC) who were Previously Treated with Chemotherapy
Maintenance Daily Oral Etoposide Versus No Further Therapy Following Induction Chemotherapy With Etoposide Plus Ifosfamide Plus Cisplatin In Extensive Small Cell Lung Cancer
Phase III Trial of Maintenance Daily Oral VP-16 Versus No Further Therapy Following Induction Chemotherapy With VP-16 (V) Plus Ifosfamide (I) Plus Cisplatin (P) (VIP) In Extensive Small Cell Lung Cancer (SCLC)
A Phase III Hoosier Oncology Group Study of Thoracic Radiotherapy (TRT) Plus Cisplatin (P) and Vinblastin (V) With or Without Hydroxyurea (HX) for Locally Unresectable Non-Small Cell Lung Cancer (NSCLC)
Randomized Phase III Study of Cisplatin (P) and Vinblastine (V) Followed by Thoracic Radiotherapy With or Without Hydroxyurea (HX) In Previously Untreated Limited Unresectable Non-Small Cell Lung Cancer (NSCLC)
A Phase II Hoosier Oncology Group Study of VP-16 Plus Ifosfamide Plus Cisplatin (VIP) Plus Concurrent Radiation Therapy (XRT) for Previously Untreated Limited Small Cell Lung Cancer (SCLC)
A Phase III Study of VP16 plus Cisplatin (VP) alone or with Ifosfamide (VIP) in Previously Untreated Patients (PTS) with Extensive Small Cell Carcinoma of the LUNG (SCLC)
A Phase III Study of VP16 plus Cisplatin (VP) alone or with Ifosfamide (VIP) in Previously Untreated Patients with Extensive Small Cell Carcinoma of the Lung (SCLC)
Paclitaxel (P) plus bevacizumab (B) in patients (pts) with Chemosensitive Relapsed Small Cell Lung Cancer (SCLC): A Safety, Feasibility and Efficacy trial
Predictors of toxicity to consolidation docetaxel (D) following cisplatin (P) plus etoposide (E) plus concurrent radiation (XRT) in patients (pts) with stage III non-small cell lung cancer (NSCLC) treated on a phase III randomized trial
An analysis of elderly patients (pts) treated on a phase III trial of cisplatin (P) plus etoposide (E) with concurrent radiotherapy (CRT) followed by docetaxel (D) vs observation (O) in pts with stage III non small cell lung cancer (NSCLC)
Multivariate Analysis of Prognostic Variables Associated with Survival from a Phase III Study of Cisplatin (P) plus Etoposide (E) plus Chest Radiation (XRT) with or without Consolidation Docetaxel (D) in Patients with Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)
Phase III Study of Cisplatin (P) plus Etoposide (E) with Concurrent Chest Radiation (XRT) followed by Docetaxel (D) vs. Observation in Patients (pts) with Stage III Non-small Cell Lung Cancer (NSCLC): An Interim Toxicity Analysis of Consolidation Therapy
Meta-analysis of randomized trials evaluating Cisplatin or carboplatin-based concomitant chemoradiation versus radiotherapy alone in locally advanced non-small cell lung cancer
A Randomized Phase III Trial Comparing CPT-11 (Irinotecan HCl; Camptosar Injection)/Cisplatin with Etoposide/Cisplatin in Patients with Previously Untreated, Extensive, Small-Cell Lung Cancer
A phase II trial of monalizumab in combination with durvalumab (MEDI4736) plus platinum-based chemotherapy for first-line treatment of extensive stage small cell lung cancer (MOZART)
LBA71 – A multi-centre open-label randomized phase II study of osimertinib with and without ramucirumab in TKI-naïve EGFR-mutant metastatic NSCLC (RAMOSE trial interim analysis)
The association between immune-related adverse events and efficacy outcomes with consolidation pembrolizumab after chemoradiation in patients with stage III NSCLC
Phase II trial of consolidation Pembrolizumab following concurrent chemoradiation in patients (pts) with unresectable or inoperable stage III non-small cell lung cancer (NSCLC): initial safety data from HCRN LUN12-179
A randomized double-blind phase II trial of platinum (P) plus etoposide (E) with or without concurrent ZD6474 (Z) in patients (pts) with previously untreated extensive-stage (ES) small cell lung cancer (SCLC)
